You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Emerging drugs for bronchiectasis
|
---|---|
Published in |
Expert Opinion on Emerging Drugs, July 2012
|
DOI | 10.1517/14728214.2012.702755 |
Pubmed ID | |
Authors |
Anne B Chang, Robyn L Marsh, Heidi C Smith-Vaughan, Lucas R Hoffman |
Abstract |
The global burden of disease due to bronchiectasis is high, disproportionately impacting developing countries and disadvantaged populations. Bronchiectasis, the destruction and dilation of airways, is due to a variety of causes and is characterized by a self-perpetuating cycle of airway inflammation, infection and obstruction that results in substantial morbidity and mortality. Although many therapies have been tested that address each of these three components, as well as the diseases that both cause and result from bronchiectasis, there have been few randomized, placebo-controlled trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 38 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 16% |
Researcher | 5 | 13% |
Student > Ph. D. Student | 4 | 11% |
Student > Bachelor | 3 | 8% |
Lecturer | 3 | 8% |
Other | 8 | 21% |
Unknown | 9 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 50% |
Agricultural and Biological Sciences | 2 | 5% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Environmental Science | 1 | 3% |
Other | 4 | 11% |
Unknown | 9 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2018.
All research outputs
#6,384,139
of 22,687,320 outputs
Outputs from Expert Opinion on Emerging Drugs
#138
of 491 outputs
Outputs of similar age
#44,946
of 163,954 outputs
Outputs of similar age from Expert Opinion on Emerging Drugs
#2
of 6 outputs
Altmetric has tracked 22,687,320 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 491 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,954 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.